Alvotech and Teva Pharmaceuticals announced that the U.S. FDA has approved a new presentation of SELARSDI ... aligning it ...

As most advisors are well aware, high stock prices have pushed down the market’s dividend yield. Barron’s ran a screen for ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Most U.S. stocks are rising Monday and adding to the gains made during their best week of the year. The S&P 500 was up 0.2% ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent ...

Global Regenerative Medicine Market is valued at approximately USD 34.56 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 32.4% over the forecast period 2024-2032.

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...